NetraMark to Showcase AI Clinical Trial Platform at Sidoti Conference
Event summary
- NetraMark will present at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET.
- CEO George Achilleos will discuss commercial, clinical, and regulatory progress of NetraAI.
- NetraAI aims to identify patients most likely to respond to drugs in clinical trials.
- The company will also hold one-on-one meetings with investors on June 17 and 18, 2026.
The big picture
NetraMark's presentation at the Sidoti Small Cap Conference highlights the growing intersection of AI and clinical trials, where precision analytics could reduce trial failures and accelerate drug development. The company's ability to work with smaller datasets and segment patient responses could be a game-changer in an industry plagued by high costs and long timelines. Investors will be watching closely to see if NetraAI can deliver on its promise of improving trial success rates.
What we're watching
- Technology Validation
- How NetraAI's focus mechanisms will differentiate it from other AI methods in clinical trials.
- Market Adoption
- Whether pharmaceutical companies will embrace NetraAI's precision analytics for smaller datasets.
- Regulatory Progress
- The pace at which NetraMark secures regulatory approvals for its AI-driven clinical trial solutions.
Related topics